Market Place
Sourcing Support
Sandoz launches first and only biosimilar for multiple sclerosis, Tyruko
31 Jan 2024 //
GLOBENEWSWIRE
Sandoz`s Tyruko (natalizumab) Receives Approval in Europe
20 Nov 2023 //
EMA
Biogen`s Biologic Tysabri (natalizumab) Receives Approval in the U.S.
30 Oct 2023 //
FDA
Sandoz`s Tyruko (natalizumab) Receives Approval in Europe
17 Oct 2023 //
EMA
Sandoz gets EC approval for biosimilar for multiple sclerosis in Europe
27 Sep 2023 //
FINANCIAL EXPRESS
FDA Approves First Biosimilar to Treat Multiple Sclerosis
25 Aug 2023 //
FDA
Sandoz`s Biologic Tyruko (natalizumab) Receives Approval in the U.S.
24 Aug 2023 //
FDA
Sandoz receives positive CHMP opinion for multiple sclerosis biosimilar natalizumab
24 Jul 2023 //
GLOBENEWSWIRE
Biogen`s Biologic Tysabri (Natalizumab) Receives Approval in the U.S.
11 Apr 2023 //
FDA
Genentech sues Biogen for royalties on blockbuster MS drug
02 Mar 2023 //
NASDAQ
Unsealed documents detail Biogen`s fight against Sandoz Tysabri biosimilar
21 Sep 2022 //
ENPTS
Novartis asks FDA to approve biosimilar for Biogen’s top-selling MS drug
26 Jul 2022 //
BIOPHARMADIVE
Applications for proposed biosimilar natalizumab accepted by US FDA and EMA
25 Jul 2022 //
GLOBENEWSWIRE
Biogen pays $900M to resolve whistleblower`s kickbacks suit
21 Jul 2022 //
FIERCEPHARMA
Polpharma in pole position for biosimilar Tysabri in Europe
18 Jul 2022 //
PHARMAPHORUM
Biogen`s blockbuster Tysabri loses a key patent in Europe
16 Jul 2021 //
FIERCE PHARMA
Biogen won’t explain why FDA slapped down their bid for new Tysabri formulation
01 May 2021 //
ENDPTS
Biogen won’t explain why FDA slapped down their bid for new Tysabri formulation
30 Apr 2021 //
ENDPTS
Biogen Provides Regulatory Update on the (sBLA) TYSABRI® (natalizumab)
28 Apr 2021 //
GLOBENEWSWIRE
New subcutaneous formulation of Tysabri approved in UK
16 Apr 2021 //
PHARMATIMES
New subcutaneous formulation of Tysabri approved in UK
15 Apr 2021 //
NEUROEUROPE
EU nod for new formulation of Biogen`s Tysabri
08 Apr 2021 //
PHARMATIMES
BRIEF—EC green light for new subcutaneous Tysabri for MS
07 Apr 2021 //
THEPHARMALETTER
AbbVie, Biogen lead pharma in new year`s drug price hikes
05 Jan 2021 //
BIOPHARMADIVE
Drugmakers to hike prices for 2021 as pandemic, political pressure put revenues
04 Jan 2021 //
BIOPHARMADIVE
Perrigo fails to get €1.64bn tax assessment quashed by High Court
05 Nov 2020 //
RTE
Biogen Idec`s Biological Natalizumab Receives Approval In US
05 Oct 2020 //
FDA
Biogen Idec`s Tysabri (Natalizumab) Receives Supplemental Approval In US
24 Jun 2020 //
FDA
Biogen Idec`s Tysabri (Natalizumab) Receives Supplemental Approval In US
25 Apr 2020 //
FDA
Clinical Studies to Begin for Natalizumab, Aflibercept, and Bevacizumab Biosi
21 Oct 2019 //
CENTERFORBIOSIMILARS
Polpharma Bio teams up with Sandoz to commercialize Tysabri biosimilar
04 Sep 2019 //
SEEKINGALPHA
Novartis, Lonza deepen biosimilars push with MS, arthritis drug deals
04 Sep 2019 //
REUTERS
Novartis strikes marketing deal for Polpharma’s potential Tysabri biosimilar
03 Sep 2019 //
PHARMAPHORUM
Roche`s Ocrevus discount wins over England`s cost watchdogs
10 May 2019 //
FIERCE PHARMA
IRS knocks Perrigo for $873M in unpaid royalties
30 Apr 2019 //
FIERCE PHARMA
Biogen beats estimates on multiple sclerosis drugs sales
29 Jan 2019 //
REUTERS
Biogen`s Tysabri (Natalizumab) Receives Approval in US
07 Jan 2019 //
FDA
Perrigo`s $1.9B Tysabri Irish tax bill adds lingering negative: analyst
28 Dec 2018 //
FIERCE PHARMA
